These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 16436749)

  • 1. In vitro activity of DX-619, a novel des-fluoro(6) quinolone, against a panel of Streptococcus pneumoniae mutants with characterized resistance mechanisms.
    Wickman PA; Moland ES; Black JA; Thomson KS
    Antimicrob Agents Chemother; 2006 Feb; 50(2):796-8. PubMed ID: 16436749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.
    Wickman PA; Black JA; Moland ES; Thomson KS
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2255-7. PubMed ID: 16723599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases.
    Strahilevitz J; Truong-Bolduc QC; Hooper DC
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5051-7. PubMed ID: 16304172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibilities of healthcare- and community-associated methicillin-resistant staphylococci to the novel des-F(6)-quinolone DX-619.
    Watanabe S; Ito T; Hiramatsu K
    J Antimicrob Chemother; 2007 Dec; 60(6):1384-7. PubMed ID: 17890283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activity of BMS 284756, a novel des-fluoro (6) quinolone and seven fluoroquinolones against Streptococcus pneumoniae.
    Saravolatz L; Manzor O; Pawlak J; Belian B
    Clin Microbiol Infect; 2001 Oct; 7(10):572-3. PubMed ID: 11683802
    [No Abstract]   [Full Text] [Related]  

  • 6. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
    Okumura R; Hirata T; Onodera Y; Hoshino K; Otani T; Yamamoto T
    J Antimicrob Chemother; 2008 Jul; 62(1):98-104. PubMed ID: 18390884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro development of resistance to DX-619 and other quinolones in enterococci.
    Wickman PA; Black JA; Smith Moland E; Thomson KS; Hanson ND
    J Antimicrob Chemother; 2006 Dec; 58(6):1268-73. PubMed ID: 17062613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quinolone resistance mechanisms in pneumococci.
    Eliopoulos GM
    Clin Infect Dis; 2004 May; 38 Suppl 4():S350-6. PubMed ID: 15127369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of novel des-fluoro(6) quinolone BMS-284756 against mutants of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus selected with different quinolones.
    Schmitz FJ; Boos M; Mayer S; Köhrer K; Scheuring S; Fluit AC
    Antimicrob Agents Chemother; 2002 Mar; 46(3):934-5. PubMed ID: 11850293
    [No Abstract]   [Full Text] [Related]  

  • 10. Activity of DX-619 compared to other agents against viridans group streptococci, Streptococcus bovis, and Cardiobacterium hominis.
    Kosowska-Shick K; Smith K; Bogdanovich T; Ednie LM; Jones RN; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4191-4. PubMed ID: 17043120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates.
    Adam HJ; Schurek KN; Decorby MR; Weshnoweski B; Vashisht R; Karlowsky K; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2006 Jul; 58(1):202-4. PubMed ID: 16636082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of quinolone resistance in Streptococcus pneumoniae exposed in vitro to subinhibitory drug concentrations.
    Avrain L; Garvey M; Mesaros N; Glupczynski Y; Mingeot-Leclercq MP; Piddock LJ; Tulkens PM; Vanhoof R; Van Bambeke F
    J Antimicrob Chemother; 2007 Nov; 60(5):965-72. PubMed ID: 17693451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro antianaerobic activity of DX-619, a new des-fluoro(6) quinolone.
    Tanaka K; Mikamo H; Nakao K; Watanabe K
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3908-13. PubMed ID: 17065629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Quinolones and Streptococcus pneumoniae. Mechanisms of action and resistance].
    Taléns-Visconti R; Garrigues TM; Cantón E
    Rev Esp Quimioter; 2002 Dec; 15(4):313-24. PubMed ID: 12587036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility testing of Streptococcus pneumoniae and Viridans streptococcal isolates against: quinolones, oxazolidinones and glycopeptides.
    Băncescu G; Neagu AS; Radu-Popescu M; Nica M; Dascălu A; Nistor I; Bărbuceanu SF; Băncescu A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(1):286-90. PubMed ID: 23077910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of effect of DX-619, a novel des-fluoro(6)-quinolone, on glomerular filtration rate measured by serum clearance of cold iohexol.
    Sarapa N; Wickremasingha P; Ge N; Weitzman R; Fuellhart M; Yen C; Lloyd-Parks J
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1912-7. PubMed ID: 17371829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterisation of the quinolone resistance-determining regions (QRDR) including gyrA, gyrB, parC and parE genes in Streptococcus pneumoniae.
    Kakinuma Y; Maeda Y; Mason C; Goldsmith CE; Coulter WA; Matsuda M; Dooley JS; Lowery CJ; Moore JE
    Br J Biomed Sci; 2012; 69(3):123-5. PubMed ID: 23057160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro pharmacodynamic evaluation of garenoxacin against quinolone-resistant Streptococcus pneumoniae.
    Fukuda Y; Takahata M; Sugiura Y; Shinmura Y; Nomura N
    Int J Antimicrob Agents; 2012 Feb; 39(2):163-7. PubMed ID: 22088660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of quinolone susceptibility in Campylobacter jejuni associated with different gyrA mutations.
    McIver C; Hogan T; White P; Tapsall J
    Pathology; 2004 Apr; 36(2):166-9. PubMed ID: 15203753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
    J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.